Schedule and Dose for Combination Therapy

The Cancer Immunotherapy Consortium held its annual Scientific Colloquium on March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD. The meeting, “Schedule and Dose for Combination Therapy,” featured a series of plenary lectures examining how best to address the challenges of combining immune-based treatments with existing standards of care. The meeting also included an interdisciplinary roundtable discussion addressing the academia-industry interface and how it can help shape the future of Immuno-Oncology.

Introduction

• Axel Hoos, Bristol-Myers Squibb

Keynote Address

• Rafi Ahmed, Emory University

Studying Vaccination Schedules: Lessons from Infectious Diseases

• Martin G. Myers, University of Texas Medical Branch
• Yves Levy, University Paris-Est, Publique-Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier
• Rafick-Pierre Sékaly, Vaccine & Gene Therapy Institute,
• Gisela González Marinello, Center of Molecular Immunology

Schedule and Dose: Relevance for Combination Therapy

Introduction by Laurence Zitvogel, Institut Gustave Roussy

Immune Therapy & Immune Therapy

• James L. Gulley, National Cancer Institute, NIH
• Cornelis J.M. Melief, Leiden University Medical Center
• Svetomir N. Markovic, Mayo Clinic
• Robert H. Vonderheide, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine

Immune Therapy & Chemotherapy

• Tania Crombet Ramos, Center of Molecular Immunology
• Jean-Marie Cuillerot, Bristol-Myers Squibb
• Leisha A. Emens, Johns Hopkins University School of Medicine
• Hyam Levitsky, Johns Hopkins University School of Medicine
• Frédéric Triebel, Immutep S.A.

Immune Therapy & Targeted Therapies

• Charlotte E. Ariyan, Memorial Sloan-Kettering Cancer Center,
• Margaret Callahan, Memorial Sloan-Kettering Cancer Center
• Javier Pinilla-Ibarz, H. Lee Moffitt Cancer Center and Research Institute
• Antoni Ribas, University of California Los Angeles
• Lupe G. Salazar, University of Washington School of Medicine
• Laurence Zitvogel, Institut Gustave Roussy

Immune Therapy & Local Therapies

• Silvia C. Formenti, New York University School of Medicine
• Jeffrey A. Gelfand, Massachusetts General Hospital
• Ronald Levy, Stanford University School of Medicine

The Academia-Industry Interface: Crosstalk to Shape the Future of Immuno-Oncology

• Axel Hoos, Bristol-Myers Squibb
• Adam Kolom, Cancer Research Institute
• Christoph Huber, University Medical Center of the Johannes Gutenberg-University of Mainz
• Michael D. Becker, MD Becker Partners LLC

Interdisciplinary Roundtable

Moderated by Jill O’Donnell-Tormey, Cancer Research Institute & Axel Hoos, Bristol-Myers Squibb

• Michael D. Becker, MD Becker Partners LLC
• Stephen P. Creekmore, National Cancer Institute, NIH
• Tito Fojo, National Cancer Institute
• Mark W. Frohlich, Dendreon Corporation
• F. Stephen Hodi Jr., Dana-Farber Cancer Institute
• Christoph Huber, University Medical Center of the Johannes Gutenberg-University of Mainz
• Nils Lonberg, Bristol-Myers Squibb
• Michele Maio, University Hospital of Siena
• Jens-Peter Marschner, Merck Serono
• Raj K. Puri, U.S. Food & Drug Administration
• Shalini Sharp, Agenus Inc.
• Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center

Immunobiology & Immune Monitoring

Keynote Address by Mark M. Davis, Stanford University School of Medicine

Treg Homeostasis

• Mark M. Davis, Stanford University School of Medicine
• Jens G. Lohr, Dana-Farber Cancer Institute and Broad Institute
• Benoit L. Salomon, Université de Pierre et Marie Curie, Centre National de Recherche Scientifique and INSERM
• Sjoerd H. van der Burg, Leiden University Medical Center

Immune Monitoring Session

• Michael Kalos, University of Pennsylvania School of Medicine
• Cedrik M. Britten, University Medical Center of the Johannes Gutenberg-University Mainz
• Sylvia Janetzki, ZellNet Consulting, Inc.
• Lisa K. McNeil, Pfizer Vaccine Research
• Axel Hoos, Bristol-Myers Squibb